Clinical Trials Browser

Phase 3 × lorlatinib × 90 days × Clear all

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

Neuroblastoma, Ganglioneuroblastoma